Modality
Degrader
MOA
IL-13i
Target
PARP
Pathway
RAS/MAPK
RB
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
Oct 2023
→ Aug 2026
Phase 1Current
NCT08811995
1,630 pts·RB
2023-10→2026-08·Terminated
1,630 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-285mo awayPh2 Data· RB
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2026-08-28 · 5mo away
RB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08811995 | Phase 1/2 | RB | Terminated | 1630 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |